<DOC>
	<DOC>NCT01945489</DOC>
	<brief_summary>This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) compared with placebo, in achieving a 100% reduction in urinary incontinence in patients with overactive bladder (OAB) not properly managed with an anticholinergic.</brief_summary>
	<brief_title>OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients with symptoms of Overactive Bladder (OAB) (frequency and urgency) with urinary incontinence for at least 6 months prior to screening. Symptoms of OAB due to a neurological reason Use of anticholinergics or other medications or therapies to treat symptoms of OAB within 7 days of screening Use of Clean Intermittent Catheterization (CIC) or indwelling catheter to manage urinary incontinence Use of botulinum toxin therapy of any serotype for any urological condition Use of botulinum toxin therapy of any serotype for any nonurological condition in the 12 weeks prior to screening History of any pelvic or urological abnormalities, bladder surgery or disease, other than OAB, that may affect bladder function Diagnosis of Myasthenia gravis, EatonLambert syndrome, or Amyotrophic Lateral Sclerosis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>